Bio-Techne TECH

Bio-Techne Corporation continues to face significant financial challenges, reporting a quarterly revenue dip to $286.6 million in Q1 2026, which marks a 1% decline year-on-year and fell short of analysts' expectations. This has resulted in a 4.1% drop in stock price. The company's Q3 earnings report also revealed disappointing results, with revenues of $311.42 million and adjusted EPS of $0.53, which were below market expectations. Despite these setbacks, analysts remain cautiously optimistic about a potential recovery in 2026, driven by strong demand from major pharmaceutical clients and growth in its spatial biology segment, underpinned by strategic acquisitions such as the recent purchase of a 19.9% stake in Wilson Wolf for $232 million. Nonetheless, Bio-Techne's stock performance continues to be a concern, as it recently hit a 52-week low, reflecting mixed sentiments from institutional investors.